.png){kind=icon}
.png){kind=icon}
Return
AN-465 is a novel N6-methyladenosine inhibitor for the treatment of hand, foot, and mouth disease
.png){kind=icon}
OA
AI
S
X
P
H
J
X
Q
Z
B
J
L
J
J
L
J
梁
DOI：10.1038/s42003-026-10165-4.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hand, foot, and mouth disease (HFMD) is a significant infectious condition with no effective therapeutic agents currently available. Previous research has shown that inhibiting m6A can suppress the replication of Enterovirus 71 (EV71), the primary pathogen of HFMD. In this study, we identified a promising compound, AN465, superior to existing m6A inhibitor through a screening of 2.2 million compounds. We conducted a comprehensive validation of AN465 across molecular, cellular, and animal models, confirming its potent inhibitory effects on the replication of both Enterovirus 71 (EV71) and Coxsackievirus A6 (CVA6). Additionally, we elucidated the underlying molecular mechanisms in detail. Overall, this study not only identifies a novel EV71 inhibitor based on targeting the m6A methyltransferase METTL3, but also offers a promising candidate for the first specific therapeutic against EV71 and CA-V6, providing a new strategy for the treatment of HFMD. Hand, foot and mouth disease's main pathogen EV71 can be suppressed by m⁶A inhibition. Here authors identified AN465 as a promising HFMD therapeutic that targets METTL3.
Journal
IF:
5.1
Papers:
1.0W
Citations:
3.2W
Organization
Cited Papers